The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | TP53 mutations in CLL: a large retrospective analysis
Little is known about TP53 mutations and their association with adverse prognosis and chemotherapy resistance in chronic lymphocytic leukemia (CLL). Here, Florence Cymbalista, MD, of Avicenne Hospital, Bobigny, France, discusses the retrospective analysis of CLL patients with TP3 mutations from the French Innovative Leukemia Organization (FILO) Group. She highlights the need for further investigation and the importance of databases of genetic mutations. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,
